Gisela joined Oncocyte in October 2021 as the firm’s Chief Operating Officer and was promoted to President and Chief Operating Officer in August 2022. She brings a wealth of knowledge and first-hand experience, leading large-scale operations at global pharmaceutical and diagnostics companies.
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
- At Roche-Genentech, Gisela Paulsen led over 3,000 employees located in over 60 countries.
- Gisela drove drug-development innovation and R&D across 400+ late-stage and post-approval evidence-generation clinical trials with nearly 100,000 patients.
- Paulsen will oversee the Company’s product portfolio, including the pending launches of VitaGraft™ and gaining reimbursement of DetermaIO™, DetermaTx™, and DetermaCNI™.
Click image above to view full announcement.
Oncocyte is a precision diagnostics company with a mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey.
Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” “may,” and similar expressions) are forward-looking statements. These statements include those pertaining to future expectations, beliefs, goals, plans, or prospects expressed by management. Forward-looking statements involve risks and uncertainties, including, without limitation, the potential impact of COVID-19 on Oncocyte or its subsidiaries’ financial and operational results, risks inherent in the development and/or commercialization of diagnostic tests or products, uncertainty in the results of clinical trials or regulatory approvals, the capacity of Oncocyte’s third-party supplied blood sample analytic system to provide consistent and precise analytic results on a commercial scale, potential interruptions to supply chains, the need and ability to obtain future capital, maintenance of intellectual property rights in all applicable jurisdictions, obligations to third parties with respect to licensed or acquired technology and products, the need to obtain third party reimbursement for patients’ use of any diagnostic tests Oncocyte or its subsidiaries commercialize in applicable jurisdictions, and risks inherent in strategic transactions such as the potential failure to realize anticipated benefits, legal, regulatory or political changes in the applicable jurisdictions, accounting and quality controls, potential greater than estimated allocations of resources to develop and commercialize technologies, or potential failure to maintain any laboratory accreditation or certification. Actual results may differ materially from the results anticipated in these forward-looking statements and accordingly such statements should be evaluated together with the many uncertainties that affect the business of Oncocyte, particularly those mentioned in the “Risk Factors” and other cautionary statements found in Oncocyte’s Securities and Exchange Commission (SEC) filings, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Oncocyte undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Contacts:
Chelli Miller
12199216823
chelli@contentcarnivores.com
Source: Oncocyte (OCX)
Distributed by: Reportable, Inc.